(A) Differences between 4-hour fasting blood glucose levels measured at 1 pm in an HFD-fed B6J mice before and after bacterial transfer (days 7, 9, and 11) from donor HFD-fed B6J mice treated with placebo, vancomycin, or metronidazole for 1 week (n = 6 per group). (B–D) OGTT of the HF-fed B6J recipient mice performed before (white circles) and after (solid circles) bacterial transfer (day 11) from mice treated with placebo (B), vancomycin (C), or metronidazole (D) (n = 6). *P < 0.05 and **P < 0.01, by unpaired, 2-tailed t test. (E and F) Western blots for insulin signaling in liver (E) and muscle (F) of the recipient mice. (G) Western blots for insulin signaling in the liver of HFD-fed, GF B6J mice colonized with cecal bacteria from HFD-fed B6J mice treated with placebo, vancomycin, or metronidazole, measured 2 weeks after transfer. Graph shows quantitation of p-AKT protein normalized by actin (n = 4–6). (H) OGTT of HFD-fed, GF B6J mice colonized with cecal bacteria from HFD-fed B6J mice treated with placebo (circles), vancomycin (squares), or metronidazole (triangles) (n = 7–9). *P < 0.05, for placebo versus vancomycin; #P < 0.05 and ##P < 0.01, for placebo versus metronidazole, by ANOVA, followed by Tukey-Kramer post-hoc.